{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.3","upperLimit":"33.8","value":"28.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"}],"units":"Participants"}],"description":"ORR was determined in all participants and was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR). Participants with missing data were considered non-responders. Per protocol, only data generated during the initial course of treatment contributed to the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment during the initial course of treatment","reportingStatus":"POSTED","timeFrame":"Up to approximately 80.5 months","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}